Treating older men with prostate cancer: Survival (or selection) of the fittest?

JAMA

Volumn 296, Issue 22, 2006, Pages 2733-2734

  Litwin, Mark S ^a,b   Miller, David C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; EDITORIAL; ETHNICITY; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; MEDICARE; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 33845491100     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.22.2733     Document Type: Editorial

References (25)

1. Ugnat AM, Xie L, Semenciw R, Waters C, Mao Y. Survival patterns for the top four cancers in Canada: the effects of age, region and period. Eur J Cancer Prev. 2005;14:91-100.
2. Surveillance, Epidemiology, and End Results SEER Program. SEER*Stat Database: Mortality-All COD; 2005. http://seer.cancer.gov/. Accessed November 8, 2006.
3. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
4. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
5. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.
6. Wong Y-N, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683-2693.
7. Haro JM, Kontodimas S, Negrin MA, et al. Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy. 2006;5:11-25.
8. Sturmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437-447.
9. Silber JH, Rosenbaum PR, Trudeau ME, et al. Multivariate matching and bias reduction in the Surgical Outcomes Study. Med Care. 2001;39:1048-1064.
10. Malenka DJ, McLerran D, Roos N, et al. Using administrative data to describe casemix: a comparison with the medical record. J Clin Epidemiol. 1994;47:1027-1032.
11. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60:258-263.
12. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compre Canc Netw. 2005;1(suppl 1):S29-S33.
13. Scales CD, Curtis LH, Norris RD, et al. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006;176:511-514.
14. McNaughton Collins M, Stafford RS, Barry MJ. Age-specific patterns of prostate-specific antigen testing among primary care physician visits. J Fam Pract. 2000;49:169-172.
15. Ross LE, Coates RJ, Breen N, et al. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med. 2004;38:732-744.
16. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2004;96:1358-1367.
17. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129-135.
18. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141-2149.
19. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134-1141.
20. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990.
21. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23:8165-8169.
22. Carter HB, Walsh PC, Landis P, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002;167:1231-1234.
23. Whitmore WF Jr. Proceedings: the natural history of prostatic cancer. Cancer. 1973;32:1104-1112.
24. Wilt TJ, Brawer MK. The Prostate Cancer Intervention vs Observation Trial: a randomized trial comparing radical prostatectomy vs expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994;152:1910-1914.
25. Donovan J, Hamdy F, Neal D, et al; ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1-88.